Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Maximilian Stahl & Amer M. Zeidan. (2017) Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review of Hematology 10:4, pages 345-364.
Read now
Read now
Amer M. Zeidan, Maximilian Stahl & Rami Komrokji. (2016) Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 21:3, pages 283-300.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Rami S Komrokji & Amer M Zeidan. (2015) Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal of Blood Medicine 6, pages 1-16.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now
Read now
Amer M Zeidan, Thomas Prebet, Ehab Saad Aldin & Steven David Gore. (2014) Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?. Expert Review of Hematology 7:2, pages 191-194.
Read now
Read now
Amer M Zeidan & Steven D Gore. (2013) Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?. Expert Review of Hematology 6:5, pages 539-542.
Read now
Read now
Articles from other publishers (13)
Juliane Baumann, Markus Spindler, Yannick Throm, Michael Lübbert & Markus Bender. (2022) Absence of early platelet increment in healthy mice during decitabine treatment. Scientific Reports 12:1.
Crossref
Crossref
Ying Fang, Juan Guo, Dong Wu, Ling-Yun Wu, Lu-Xi Song, Zheng Zhang, You-Shan Zhao & Chun-Kang Chang. (2021) Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome. Frontiers in Oncology 10.
Crossref
Crossref
Jan Philipp Bewersdorf & Amer M. Zeidan. 2020. Diagnosis and Management of Myelodysplastic Syndromes. Diagnosis and Management of Myelodysplastic Syndromes
109
127
.
A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres, D P Steensma, A DeZern, G Roboz, E Jabbour, G Garcia-Manero, A List & R Komrokji. (2017) Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31:6, pages 1391-1397.
Crossref
Crossref
Maximilian Stahl & Amer M. Zeidan. (2017) Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 123:10, pages 1703-1713.
Crossref
Crossref
A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard, N A Ali, C Zimmerman, G Roboz, A DeZern, A Nazha, E Jabbour, H Kantarjian, S D Gore, J P Maciejewski, A List & R Komrokji. (2015) Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30:3, pages 649-657.
Crossref
Crossref
Eun-Ju Lee, Nikolai Podoltsev, Steven D. Gore & Amer M. Zeidan. (2016) The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 30:1, pages 1-10.
Crossref
Crossref
Amer M. Zeidan, Mikkael A. Sekeres, Xiao‐Feng Wang, Najla Al Ali, Guillermo Garcia‐Manero, David P. Steensma, Gail Roboz, John Barnard, Eric Padron, Amy DeZern, Jaroslaw P. Maciejewski, Alan F. List & Rami S. Komrokji. (2015) Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology 90:11, pages 1036-1040.
Crossref
Crossref
Aziz NazhaMikkael A. SekeresSteven D. Gore & Amer M. Zeidan. (2015) Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. The Oncologist 20:9, pages 1069-1076.
Crossref
Crossref
Amer M. Zeidan, Steven D. Gore, Eric Padron & Rami S. Komrokji. (2015) Current state of prognostication and risk stratification in myelodysplastic syndromes. Current Opinion in Hematology 22:2, pages 146-154.
Crossref
Crossref
Amer M. Zeidan, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Rhett P. Katterling, Martin S. Tallman & Steven D. Gore. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal of Haematology 167:1, pages 62-68.
Crossref
Crossref
Amer M. Zeidan, Mohamed A. Kharfan-Dabaja & Rami S. Komrokji. (2014) Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion in Hematology 21:2, pages 123-130.
Crossref
Crossref
Amer M. Zeidan, Yuliya Linhares & Steven D. Gore. (2013) Current therapy of myelodysplastic syndromes. Blood Reviews 27:5, pages 243-259.
Crossref
Crossref